Femoropopliteal Artery Stent Thrombosis

Original Title: Femoropopliteal Artery Stent Thrombosis. Report from the Excellence in Peripheral Artery Disease Registry. Reference: Subhash Banerjee et al. Circ Cardiovasc Interv. 2016 Feb;9(2):e002730.

 

There is limited information on peripheral stent thrombosis and involved factors.

This study analyzed 604 stent procedures in femoropopliteal territory form the multicenter registry “Excellence in Peripheral Artery Disease”.

Stent thrombosis occurred in 26 of the 604 patients (4.3%) at median 6 month follow up post procedure.

Stent thrombosis was more frequent in men and when the lesion originally treated was a chronic total occlusion.

There were no differences in stent thrombosis between drug-coated and bare metal stents (4.4% vs 3.4%; p=0.55) but there were differences between self-expandable covered stents vs. conventional bare metal stents (10.6% vs 3.4%; p=0.02).

Thrombosis was associated to a much higher risk of adverse events over the same treated limb (HR, 4.99; CI 95% 2.31 to 10.77; p<0.001).

Multivariable analysis showed that chronic total occlusion (OR, 3.46; IC 95% 0.98 a 12.20; p=0.05) and in-stent restenosis (OR, 5.30; IC 95%, 1.83 a 15.32; p=0.002) were independently associated with stent thrombosis.

Conclusion
This multicenter registry of peripheral intervention showed that femoropopliteal stent thrombosis is 4.3% and is associated to the treatment of chronic total occlusions and restenosis of previous stents. Thrombosis is strongly associated to adverse events in this lower limb.

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Treatment of Atrial Functional Mitral Regurgitation

Atrial functional mitral regurgitation (aFMR), which results from atrial dilation without significant left ventricular dysfunction, accounts for approximately one-third of mitral regurgitation (MR) cases...

ACURATE Neo2 Underexpansion: Prevalence and Clinical Implications

While transcatheter aortic valve replacement (TAVR) provides durable clinical benefits across a wide range of patients, technical challenges remain that may affect long-term outcomes....

Spontaneous Left Main Dissection: Clinical Characteristics, management and Outcomes

Courtesy of Dr. Juan Manuel Pérez. Spontaneous left main dissection in an uncommon, and potentially life-threatening, cause of acute MI. The aim of this study,...